臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

???ui.leftmenu.abouttair???
	???ui.leftmenu.explanation???

???ui.leftmenu.bartitle???
	Repositories
	Author
	Title
	Date
	???ui.leftmenu.statisticschart???
	???ui.leftmenu.realtimefacts???
	???ui.leftmenu.trend???

???index.news???
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

???ui.leftmenu.copyrighttitle???
	???ui.leftmenu.copyrightpublisher???
	???ui.leftmenu.copyrightconference???

???ui.leftmenu.link???
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"yu m l"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1???	???jsp.browse.items-by-author.order2???

Showing items 141-165 of 237 (10 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page

Institution	Date	Title	Author
臺大學術典藏	2021-07-03T03:33:38Z	Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan	Hsieh M.-H.; Yeh M.-L.; Su T.-H.; Liu T.-W.; Huang C.-F.; Huang C.-I.; Wang S.-C.; Huang J.-F.; Dai C.-Y.; Kao J.-H.; Chuang W.-L.; PEI-JER CHEN; Liu C.-J.; Yu M.-L.
臺大學術典藏	2021-07-03T03:33:34Z	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions	Yu M.-L.;Hung C.-H.;Huang Y.-H.;Peng C.-Y.;Lin C.-Y.;Cheng P.-N.;Chien R.-N.;Hsu S.-J.;Liu C.-H.;Huang C.-F.;Su C.-W.;Huang J.-F.;Liu C.-J.;Kao J.-H.;Chuang W.-L.;Pei-Jer Chen;Chen D.-S.; Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; Liu C.-H.; Huang C.-F.; Su C.-W.; Huang J.-F.; Liu C.-J.; Kao J.-H.; Chuang W.-L.; PEI-JER CHEN; Chen D.-S.
臺大學術典藏	2021-07-03T03:33:27Z	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy	Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-07-03T03:33:25Z	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population	Yu M.-L.; PEI-JER CHEN; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L.
臺大學術典藏	2021-07-03T03:33:23Z	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations	Yu M.-L.; PEI-JER CHEN; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L.
臺大學術典藏	2021-07-03T03:33:19Z	Ropeginterferon alfa-2b every 2?weeks as a novel pegylated interferon for patients with chronic hepatitis B	Huang Y.-W.; Hsu C.-W.; Lu S.-N.; Yu M.-L.; Su C.-W.; Su W.-W.; Chien R.-N.; Hsu C.-S.; Hsu S.-J.; Lai H.-C.; Qin A.; Tseng K.-C.; PEI-JER CHEN
臺大學術典藏	2021-05-24T07:20:50Z	HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses	Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; CHEN-HUA LIU; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S.
臺大學術典藏	2021-05-24T07:20:49Z	Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy	Tseng T.-C.; Yu M.-L.; Liu C.-J.; Lin C.-L.; Huang Y.-W.; Hsu C.-S.; CHEN-HUA LIU; Kuo S.F.-T.; Pan C.J.-H.; Yang S.-S.; Su C.-W.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:44Z	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up	Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; CHEN-HUA LIU; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J.
臺大學術典藏	2021-05-24T07:20:44Z	Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin	Yu M.-L.; CHEN-HUA LIU; Huang C.-F.; Tseng T.-C.; Huang J.-F.; Dai C.-Y.; Lin Z.-Y.; Chen S.-C.; Wang L.-Y.; Juo S.-H.H.; Chuang W.-L.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:43Z	Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion	Yang H.-C.; Chen C.-L.; Shen Y.-C.; Peng C.-Y.; Liu C.-J.; Tseng T.-C.; Su T.-H.; Chuang W.-L.; Yu M.-L.; Dai C.-Y.; CHEN-HUA LIU; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:42Z	Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype	Huang C.-F.; Yu M.-L.; Kao J.-H.; Tseng T.-C.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Lin Z.-Y.; Chen S.-C.; Wang L.-Y.; Juo S.H.H.; Chuang W.-L.; CHEN-HUA LIU
臺大學術典藏	2021-05-24T07:20:40Z	Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial	CHEN-HUA LIU; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Chen S.-I.; Lin J.-W.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:34Z	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial	CHEN-HUA LIU; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Lee C.-Y.; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:34Z	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial	CHEN-HUA LIU; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L.
臺大學術典藏	2021-05-24T07:20:33Z	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial	CHEN-HUA LIU; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L.
臺大學術典藏	2021-05-24T07:20:29Z	Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients	Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; Kao J.-T.; Chen C.-C.; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; CHEN-HUA LIU; Peng C.-Y.; Kao J.-H.; Yu M.-L.; Chuang W.-L.; Chen C.-J.
臺大學術典藏	2021-05-24T07:20:26Z	Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan	CHEN-HUA LIU; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:24Z	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions	Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; CHEN-HUA LIU; Huang C.-F.; Su C.-W.; Huang J.-F.; Liu C.-J.; Kao J.-H.; Chuang W.-L.; Chen P.-J.; Chen D.-S.
臺大學術典藏	2021-05-24T07:20:23Z	Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study	CHEN-HUA LIU; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:22Z	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium	Huang C.-F.; Iio E.; Jun D.W.; Ogawa E.; Toyoda H.; Hsu Y.-C.; Haga H.; Iwane S.; Enomoto M.; Lee D.H.; Wong G.; CHEN-HUA LIU; Tada T.; Chuang W.-L.; Cheung R.; Hayashi J.; Tseng C.-H.; Yasuda S.; Tran S.; Kam L.; Henry L.; Jeong J.Y.; Nomura H.; Park S.H.; Nakamuta M.; Huang J.-F.; Tai C.-M.; Lo G.-H.; Lee M.-H.; Yang H.-I.; Kao J.-H.; Tamori A.; Eguchi Y.; Ueno Y.; Furusyo N.; Tanaka Y.; Yu M.-L.; Nguyen M.H.; For the REAL-C Investigators
臺大學術典藏	2021-05-24T07:20:19Z	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy	Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; CHEN-HUA LIU; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:18Z	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population	Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; CHEN-HUA LIU; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L.
臺大學術典藏	2021-05-24T07:20:17Z	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)	Huang C.-F.; Lai H.-C.; Chen C.-Y.; Tseng K.-C.; Kuo H.-T.; Hung C.-H.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; Kao J.-H.; Liu C.-J.; CHEN-HUA LIU; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; Yu M.-L.
臺大學術典藏	2021-05-24T07:20:17Z	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations	Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; CHEN-HUA LIU; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L.

Showing items 141-165 of 237 (10 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page

	English \| 正體中文 \| 简体中文 \| 2823024
	???header.visitor??? : 30233509 ???header.onlineuser??? : 923 ???header.sponsordeclaration???